MedPal AI Records 26 Percent Share Price Gain Following Pharmacy Dispensing Milestone

Shares in MedPal AI, the AIM-listed digital health company specialising in artificial intelligence solutions, advanced 26 per cent to 2.99 pence on Tuesday following the release of record dispensing volumes at its wholly owned pharmacy subsidiary, MedPal Limited.

The company reported that it dispensed 41,600 prescription items during March 2026, marking the highest monthly total since commencing operations. The figure represents month-on-month growth of 27.5 per cent and brings cumulative items dispensed since launch to approximately 200,000.

Management indicated that pharmacy operations now generate annualised turnover exceeding £5 million based on March volumes, with gross margins surpassing 34 per cent. The board attributed the margin performance to operational leverage derived from the company’s automated robotic dispensing infrastructure.

MedPal AI launched its pharmacy platform in October 2025 and has scaled to current volumes without proportionate increases in fixed costs, a dynamic management believes will drive further margin expansion as volumes continue to grow.

The board identified several key growth drivers, including expanded NHS Distance Selling Pharmacy volumes, sustained demand for GLP-1 weight-loss treatments through its MedPal.clinic platform, and substantial remaining capacity within its existing robotic dispensing infrastructure.

Chief Executive Jason Drummond characterised the growth rate as demonstrating “the power of our vertically integrated, AI-driven model” and suggested that the traditional pharmacy model “is being disrupted, and MedPal is leading that disruption.”

The company emphasised that its robotic infrastructure possesses the capacity to accommodate significantly higher volumes without proportionate cost increases, suggesting potential for further operating leverage as the business scales.